AstraZeneca
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.11 | 33 |
| immunology | ×0.73 | 3 |
| rareDisease | ×0.70 | 3 |
| cardiovascular | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.43 | 15 |
| phase 1 | ×0.88 | 12 |
| phase 3 | ×1.32 | 7 |
| preclinical | ×0.89 | 5 |
| phase 2 | ×1.12 | 4 |
| discovery | ×0.70 | 4 |
Strategy profile
Based on 15 disclosed transactions, AstraZeneca concentrates its licensing activity in Oncology, Immunology, and Cardiovascular. AstraZeneca pays a 1.05x premium over market median, with the strongest premiums in Cardiovascular (1.50x). Their most common deal structure is License, with an average disclosed value of $1.8B. Most recent activity: 2024.
Premium by therapeutic area
How AstraZeneca pays relative to peer medians in each TA
Pipeline coverage & gaps
AstraZeneca has disclosed activity in 4 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $91M | $1.4B |
| AcquisitionPrimary | 6 | $1.1B | $1.7B |
| Co Development | 2 | $579M | $4.1B |
| Option | 1 | $100M | $425M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | egfr_solid_tumors | Pinetree Therapeutics | egfr_solid_tumors | preclinical | $50M | $500M |
| 2024 | breast | Astellia Oncology | breast | phase_1 | $100M | $425M |
| 2024 | autoimmune | Numab Therapeutics | autoimmune | phase_1 | $50M | $1.2B |
| 2024 | WEE1 | Deciphera Pharmaceuticals | Ovarian | phase_2 | $470M | $3.2B |
| 2024 | PD-L1-tinib | TCR2 Therapeutics | Sarcoma | phase_2 | $157M | $1.3B |
| 2024 | prostate | Convergent Therapeutics | prostate | phase_1 | $100M | $1.8B |
| 2024 | hypoparathyroidism | Amolyt Pharma | hypoparathyroidism | phase_3 | $800M | $1.1B |
| 2024 | solid_tumors | Fusion Pharmaceuticals | solid_tumors | phase_2 | $2.4B | $2.4B |
| 2024 | cardiovascular | CSPC Pharmaceutical | cardiovascular | preclinical | $100M | $2.0B |
| 2024 | Allogeneic CAR-T for autoimmune | Gracell Biotechnologies | Systemic Lupus Erythematosus | phase_1 | $1.2B | $1.2B |
| 2023 | ECC5004 | Eccogene | Obesity, Type 2 Diabetes | phase_1 | $185M | $1.8B |
| 2023 | solid_tumors | Mariana Oncology | solid_tumors | preclinical | $450M | $450M |
| 2023 | breast_her2 | Daiichi Sankyo | breast_her2 | phase_3 | $1.0B | $6.9B |
| 2023 | hypertension | CinCor Pharma | hypertension | phase_2 | $1.3B | $1.8B |
| 2022 | AZD0901 (SKB264-related) | Kelun-Biotech | Multiple solid tumors | preclinical | $63M | $1.0B |
How this is computed
For each AstraZeneca deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 47 disclosed deal premiums vs. peer medians. Raw premium 1.047, clamped to [0.7, 1.5].